TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
about
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human gliomaRegulation of immune cell function and differentiation by the NKG2D receptorNK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinomaImmunotherapy for primary brain tumors: no longer a matter of privilegeNKG2D ligands as therapeutic targetsFrom pathogenesis to clinical application: insights into exosomes as transfer vectors in cancerTGF-β signaling and its targeting for glioma treatmentRAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicityValproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.Interleukin 10 decreases MICA expression on melanoma cell surface.Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.Regulation and gene expression profiling of NKG2D positive human cytomegalovirus-primed CD4+ T-cells.Oncogenic stress sensed by the immune system: role of natural killer cell receptorsGenetics, genomics, and evolutionary biology of NKG2D ligands.Recognition of tumors by the innate immune system and natural killer cells.APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.Modulation of NKG2D expression in human CD8(+) T cells corresponding with tuberculosis drug curePRL-3 mediates the protein maturation of ULBP2 by regulating the tyrosine phosphorylation of HSP60Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma.The cancer stem cell subtype determines immune infiltration of glioblastoma.TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune ResponseNKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D.Dendritic cell-based active specific immunotherapy for malignant glioma.Human natural killer cells.NK cells and cancer immunosurveillance.NKG2D ligands in tumor immunity.Immune-checkpoint blockade and active immunotherapy for glioma.A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.MICA Expression Is Regulated by Cell Adhesion and Contact in a FAK/Src-Dependent Manner.The TGF-β-induced up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization of SP1.Effect of NKG2D ligand expression on host immune responsesCancer immunoediting in malignant glioma.Targeting NKG2D in tumor surveillance.Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response.Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.Regulation of self-ligands for activating natural killer cell receptors.
P2860
Q24615166-A506B29B-210C-4201-915E-99285339A210Q24635093-656AA078-C55E-453D-9D8B-39F0BACD5F28Q27001052-938CF4CA-F9FB-4ACF-BA84-D1B09323DFA7Q27002510-900360AF-A59E-4C86-844F-AB989643F573Q27014888-F52EF12D-9270-4EFC-A701-15B609EDFAE5Q28067159-0D4D7932-C930-49CC-BEDD-1717EA540CCFQ28082042-7ACE5E33-4156-4F42-A71E-237AFB3BCF1EQ28300038-C32994A5-266C-4F27-83C0-7EC7C72DC3AEQ33825014-969DD3B8-FD8D-481D-ADF3-BFEABEEA059FQ34131549-470A62E9-B9DD-4C59-9F65-89B46B78A0C7Q34144695-8E9B3E0B-8EFC-402F-BF34-A53B8EBF77F2Q34365811-E42E41FA-456B-467F-BE23-1A3FD356968CQ34368956-BD56D3B3-7B90-447E-90EE-19645F46267BQ34473267-F51F38C6-4AB8-4719-903A-7ED073DB7327Q34489980-F852E3DA-FA05-4401-8CBD-AF55F4E9F400Q34496462-3A511799-D141-4F08-93A1-1193097FAB0EQ34722539-7E3EB5EA-19C4-49D1-B28D-2F07A61598DDQ34770719-F30E7948-E84C-4F9A-B1E2-D859CAF077A8Q34905582-27DBEB56-BE99-4A79-968A-21F93A898BFDQ35163691-D710D466-F80C-4DBE-B9EA-D412E61EE851Q35587132-E5883B08-C46E-4C52-A678-F63ADBBB5D1BQ36297010-3C80EF89-2E9C-4F9C-BA2C-0FBBA1EC8A3EQ36378043-6610570B-F5BE-4459-96E5-F345E084B206Q36484325-62A65D40-3FD9-4D05-9ADC-65C37FCBCAAAQ36715028-B881C578-AF3D-473D-8A66-298B5F826D41Q36764903-2464414E-C72C-4B49-A8F8-132A31E5BF65Q36787596-46863944-3CE5-49A3-A2E7-6A413BF6D1F5Q37287176-235FBC48-1909-4EAA-835D-A3B76ECEEC28Q37287179-3A6B2931-9A2B-41F4-AAE8-9738546528AFQ37420586-6C668CE0-B346-4541-8BCC-7B03883B4750Q37580507-8B85A6A7-1202-49CB-B6EF-E5D2F072DCF0Q37592694-28C76AD7-071C-4C78-ADF9-4C8EB9540C95Q37747352-16573E00-19AD-441B-AAF8-1D53016637C8Q37764003-7FB54B3B-E039-4BF5-9461-2AA483F70DDBQ37986999-28E04C9F-5446-4DFD-952A-FFAF01A98CEBQ38005176-95AEB499-ACAB-4A40-88A3-4B8CD21ADCFEQ38008345-196579CD-8C87-4048-8952-EFCB6B0AECC3Q38093572-AA55C396-0A98-4C56-A3FF-79D549FE20B3Q38107250-F9C1FE8C-A16A-4E6A-B569-E114CE043811Q38108820-3929DFB0-882A-4186-9ADE-C08F9BA03497
P2860
TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
TGF-beta and metalloproteinase ...... ion on malignant glioma cells.
@en
type
label
TGF-beta and metalloproteinase ...... ion on malignant glioma cells.
@en
prefLabel
TGF-beta and metalloproteinase ...... ion on malignant glioma cells.
@en
P50
P356
P1433
P1476
TGF-beta and metalloproteinase ...... ion on malignant glioma cells.
@en
P2093
Günter Eisele
Inja Waldhauer
P304
P356
10.1093/BRAIN/AWL205
P407
P50
P577
2006-08-03T00:00:00Z